EdiGene is a clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs. Anchored by its proprietary technologies of gene editing, bioinformatics, and high throughput genome-editing screening, EdiGene advances the pipeline on therapeutic platforms of LEAPER-based in vivo RNA base editing, ex vivo gene-editing hematopoietic stem cells, and ex vivo gene-editing T cells for allogeneic CAR-T.
Looking for a particular EdiGene Inc. employee's phone or email?
The EdiGene Inc. annual revenue was $29.6 million in 2026.
Zhang W is the Senior Director of Pre-clinical Evaluation of EdiGene Inc..
23 people are employed at EdiGene Inc..
EdiGene Inc. is based in Changping District, Beijing.
The NAICS codes for EdiGene Inc. are [541, 54, 62151, 621, 3254, 32, 6215, 325, 325413, 32541, 62].
The SIC codes for EdiGene Inc. are [28, 87, 873].